Zhitong Finance App News, Junshi Biotech (01877) announced that recently, the company received the “Drug Supplement Application Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) to approve the transition from conditional approval to routine approval for treprilizumab injection (product name: Tuoyi®, product code: JS001) as a single drug for platinum-containing chemotherapy failure, including progressing within 12 months of new adjuvant or adjuvant chemotherapy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.